GlassScriptPhysician profile
Jeffrey Paul
NPI 1285779900
$5,108.84
in general payments reported to CMS, 2019-2025
19 companies · $632 in 2025
The $632 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $533 · 2021: $833 · 2022: $763 · 2023: $377 · 2024: $767 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $713.18 | 2022-2025 | Rocklatan, Rhopressa, Clareon |
| Aerie Pharmaceuticals, INC. | $675.17 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $387.23 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $364.50 | 2023-2024 | Vyzulta, Miebo, Envista Mx60 Iol |
| Allergan, INC. | $344.15 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $315.33 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $314.71 | 2019-2021 | |
| Oyster Point Pharma, INC. | $305.50 | 2022-2024 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $300.55 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $263.88 | 2019-2021 | |
| Abbvie INC. | $249.92 | 2022-2025 | |
| Horizon Therapeutics Plc | $229.93 | 2020-2022 | |
| Amgen INC. | $125.00 | 2024 | |
| Shire North American Group INC | $123.21 | 2019 | |
| Astellas Pharma US INC | $122.88 | 2024 | Izervay |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $120.73 | 2021 | |
| Novo Nordisk INC | $116.80 | 2022 | |
| Spark Therapeutics, INC. | $21.27 | 2022 | |
| Ocular Therapeutix, INC. | $14.90 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.